206 related articles for article (PubMed ID: 16966430)
1. Persistent expression of autoantibodies in SLE patients in remission.
Yurasov S; Tiller T; Tsuiji M; Velinzon K; Pascual V; Wardemann H; Nussenzweig MC
J Exp Med; 2006 Oct; 203(10):2255-61. PubMed ID: 16966430
[TBL] [Abstract][Full Text] [Related]
2. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
3. Defective B cell tolerance checkpoints in systemic lupus erythematosus.
Yurasov S; Wardemann H; Hammersen J; Tsuiji M; Meffre E; Pascual V; Nussenzweig MC
J Exp Med; 2005 Mar; 201(5):703-11. PubMed ID: 15738055
[TBL] [Abstract][Full Text] [Related]
4. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.
Nakano S; Morimoto S; Suzuki J; Nozawa K; Amano H; Tokano Y; Takasaki Y
Rheumatology (Oxford); 2008 Feb; 47(2):145-9. PubMed ID: 18160420
[TBL] [Abstract][Full Text] [Related]
5. The V(lambda)-J(lambda) repertoire of patients with systemic lupus erythematosus manifests characteristics of the natural antibody repertoire.
Lee J; Cho YJ; Lipsky PE
Arthritis Rheum; 2004 Aug; 50(8):2604-14. PubMed ID: 15334475
[TBL] [Abstract][Full Text] [Related]
6. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of cellular FLICE-inhibitory protein in peripheral blood B lymphocytes in patients with systemic lupus erythematosus is associated with clinical characteristics.
Tao J; Dong J; Li Y; Liu YQ; Yang J; Wu Y; Li L; Shen GX; Tan ZJ; Tu YT
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):433-7. PubMed ID: 19335730
[TBL] [Abstract][Full Text] [Related]
9. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
[TBL] [Abstract][Full Text] [Related]
10. Predominant autoantibody production by early human B cell precursors.
Wardemann H; Yurasov S; Schaefer A; Young JW; Meffre E; Nussenzweig MC
Science; 2003 Sep; 301(5638):1374-7. PubMed ID: 12920303
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.
Figueredo MA; Rodriguez A; Ruiz-Yagüe M; Romero M; Fernandez-Cruz A; Gomez-de la Concha E; Patiño R
J Rheumatol; 2006 Oct; 33(10):1980-6. PubMed ID: 17014014
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
Cambridge G; Leandro MJ; Teodorescu M; Manson J; Rahman A; Isenberg DA; Edwards JC
Arthritis Rheum; 2006 Nov; 54(11):3612-22. PubMed ID: 17075806
[TBL] [Abstract][Full Text] [Related]
13. B cell loss leading to remission in severe systemic lupus erythematosus.
Tarrant TK; Frazer DH; Aya-Ay JP; Patel DD
J Rheumatol; 2003 Feb; 30(2):412-4. PubMed ID: 12563705
[TBL] [Abstract][Full Text] [Related]
14. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
15. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Aringer M; Steiner G; Graninger WB; Höfler E; Steiner CW; Smolen JS
Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions.
Tan Y; Yu F; Yang H; Chen M; Fang Q; Zhao MH
Hum Immunol; 2008 Dec; 69(12):840-4. PubMed ID: 18852001
[TBL] [Abstract][Full Text] [Related]
17. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus.
Hostmann A; Jacobi AM; Mei H; Hiepe F; Dörner T
Lupus; 2008 Dec; 17(12):1064-9. PubMed ID: 19029273
[TBL] [Abstract][Full Text] [Related]
18. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them.
Böhm I
Biomed Pharmacother; 2004 Jun; 58(5):338-43. PubMed ID: 15194170
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of neuro-reactive autoantibodies in neuro-psychiatric systemic lupus erythematosus].
Lu XY; Ye S; Wang Y; Guo L; Chen XX; Fan W; Wang XD; Gu YY; Bao CD; Liu Q
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2462-6. PubMed ID: 17156673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
